Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Current Investments: 2018-2025

Historic Cash & Current Investments for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $287.3 million.

  • Whitehawk Therapeutics' Cash & Current Investments rose 358.75% to $287.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.0 million, marking a year-over-year increase of 129.09%. This contributed to the annual value of $47.2 million for FY2024, which is 56.60% down from last year.
  • Whitehawk Therapeutics' Cash & Current Investments amounted to $287.3 million in Q3 2025, which was up 37.14% from $209.5 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Cash & Current Investments peaked at $287.3 million during Q3 2025, and registered a low of $36.8 million during Q2 2021.
  • In the last 3 years, Whitehawk Therapeutics' Cash & Current Investments had a median value of $119.3 million in 2023 and averaged $138.1 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Cash & Current Investments spiked by 3,244.31% in 2021, and later tumbled by 56.60% in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Cash & Current Investments (Quarterly) stood at $149.0 million in 2021, then rose by 15.82% to $172.6 million in 2022, then tumbled by 36.92% to $108.8 million in 2023, then crashed by 56.60% to $47.2 million in 2024, then spiked by 358.75% to $287.3 million in 2025.
  • Its last three reported values are $287.3 million in Q3 2025, $209.5 million for Q2 2025, and $231.1 million during Q1 2025.